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Since their initial generation in the mid 1990s, transgenic mouse models of Alzheimers’s disease (AD) have been proven to be
valuable model systems which are indispensable for modern AD research. Whereas most of these models are characterized by
extensive amyloid plaque pathology, inﬂammatory changes and often behavioral deﬁcits, modeling of neuron loss was much less
successful. The present paper discusses the current achievements of modeling neuron loss in transgenic mouse models based on
APP/Aβ and Tau overexpression and provides an overview of currently available AD mouse models showing these pathological
alterations.
1.Introduction
Alzheimer’s disease (AD) represents the most frequent form
of dementia and is characterized by two major neuropatho-
logical hallmarks: (i) extracellular plaques composed of the
40–42 residues Aβ peptide [1] and (ii) neuroﬁbrillary tangles
(NFTs), consisting of abnormal phosphorylated Tau protein
[2]. There is increasing evidence that, in addition to the well-
known extracellular amyloid deposition in the parenchyma,
Aβ peptides accumulate within neurons [3]. It has been
hypothesized that this initial accumulation is one of the
earliest pathological events, which is able to trigger the
cascade leading to neurodegeneration [4]. Whereas the vast
majority of AD cases occur sporadically, a small percentage
(<2%) of all cases represents familial forms of AD with an
autosomal dominant mode of inheritance. Identiﬁcation of
theunderlyingmutationsopenedmanifoldopportunitiesfor
thegenerationoftransgenicmousemodels.Sincetheirinitial
generation in the mid 1990s, transgenic mice have been
proven to represent valuable model systems reﬂecting vari-
ous pathological aspects of AD including plaque deposition,
inﬂammatorychangesorbehavioralabnormalities(reviewed
in [5, 6]). In the present short paper, we summarize the
current achievements of modeling neuron loss in transgenic
mice based on APP/Aβ overexpression.
2. APP-/Aβ-BasedMouseModelswith
Neuron Loss
A variety of diﬀerent transgenic AD mouse models have
been developed during the last 15 years which can be
categorized as either APP single transgenic mice (e.g., PD-
APP [7], Tg2576 [8], APP/Ld [9], TgCRND8 [10], APP23
[11], tg APP ArcSwe [12], APP-Au [13], or APPE693Δ [14]),
bigenic mice expressing both APP and PS1/PS2 or Tau
(e.g., APPswe/PS1dE9 [15], APP/PS1 [16], PS2APP [17],
APP/PS1KI [18], or APP/tau [19]), and triple transgenic
mice expressing APP, PS1, and Tau (e.g., 3xTg [20]o r
TauPS2APP [21]). Whereas most of these models present
abundant extracellular amyloid plaque pathology, several
eﬀorts modelling signiﬁcant neuron loss remained less
successful [22, 23].
First evidence for neurotoxic in vivo properties of Aβ
came from a transgenic mouse model expressing murine
Aβ under the control of the mouse Neuroﬁlament-light
gene (NF-L) promoter, ensuring neuronal expression. This
resulted in abundant neurodegeneration, with biochemical
and morphological evidence for an apoptotic mechanism
[24]. Later, a transgenic mouse model expressing human
APP with the Swedish mutation (APP23) under the con-
trol of the murine Thy1-promoter was reported, showing2 International Journal of Alzheimer’s Disease
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Figure 1: Hippocampal neuron loss in the APP/PS1KI mouse model of AD. (a) APP (brown) and Aβ staining (green) in the hippocampal
formation of a 2-month-old and (c) a 10-month-old APP/PS1KI mouse. (b,d) Higher magniﬁcation of the CA1 granular cell layer of a
2-month-old (b) and a 10-month-old APP/PS1KI reveals profound neuron loss at the later time point. Scale bars: (a,c): 200μm, (b,d):
50μm.
signiﬁcant hippocampal CA1 neuron loss (−14%) at the age
of 14 to 18 months. These mice show an age-dependent
extracellular plaque deposition primarily in neocortex and
hippocampus, accompanied by severe gliosis. The number
of CA1 neurons is inversely correlated with CA1 plaque
load and neuron loss was observed primarily in the vicinity
of extracellular plaques [25]. It has been shown that focal
neuronal toxicity is associated with extracellular Aβ deposits
whentheyoccurinaﬁbrillarbeta-pleatedsheetconﬁrmation
[26]. Surprisingly, no diﬀerences in the neocortical synaptic
bouton number as well as in synaptophysin protein levels
were detected during aging or in comparison with age-
matched nontransgenic control mice [27].
Analysis of 17-month-old APP751SL/PS1M146L trans-
genic mice using unbiased stereologic methods revealed a
loss of CA1-3 neurons in a magnitude of ∼30% compared to
age-matched PS1 control animals. Interestingly, the plaque
load was approximately 10% smaller than the level of
hippocampal pyramidal cell loss in these mice, indicating a
loss of neurons at sites of Aβ aggregation but also clearly
observedinareasdistantfromextracellularAβ deposits. This
observation points to the potential involvement of more
than one mechanism in hippocampal neuron loss in this
mouse model [29]. A quantitative study of synaptophysin-
immunoreactive presynaptic boutons (SIPBs) revealed an
age-related loss in both APP751SL and PS1M146L single
transgenic mice within the stratum radiatum, which was
most severe in APP751SL/PS1M146L mice extending also to
plaque-free regions [30].
Another model showing a more severe hippocampal
neuron loss is the APP/PS1KI mouse model [18]. At the
age of 10 months an extensive neuron loss (>50%) in
the hippocampus was reported, that correlated with the
accumulation of intraneuronal Aβ and Thioﬂavin-S positive
intracellularmaterial[18](Figure 1).Extendingthesestudies
to earlier ones revealed that this CA1 neuron loss is already
detectable at the age of 6 months. At this time point,
a loss of 33% of CA1 pyramidal neurons compared to
PS1KI littermates could be demonstrated, together with a
decreaseintheCA1volume(−30%),anatrophyoftheentire
hippocampus of 18% and synaptic alterations, including
reduced levels of pre- (SNAP25, clathrin light chain) and
post-synaptic markers (PSD-95). In addition, recordings of
ﬁeld excitatory postsynaptic potentials (fEPSPs) revealed a
signiﬁcant reduction of 6 months in APP/PS1KI compared
to PS1KI or nontransgenic mice [31]. A detailed stereo-
logical comparison of neuronal numbers in frontal cortex
and thalamus, representing brain areas with intra- and
extracellular Aβ accumulation (frontal cortex) or with only
extracellular Aβ pathology (thalamus), revealed an early loss
of cortical neurons starting at the age of 6 months. This
neuronal loss correlated with the transient intraneuronalInternational Journal of Alzheimer’s Disease 3
Table 1: Overview of transgenic AD mouse models in which neuronal loss and/or intraneuronal Aβ accumulation has been reported. In
addition, information on the transgene, extracellular plaque onset, and intraneuronal Aβ accumulation are given. (n.d.: not determined).
Transgenic
mouse model
Mutation
APP Mutation PS1 Promoter Plaque
onset Intraneur. Aβ Neuron loss Synaptic
dysfunction Reference
NF-L-Aβ — — NF-L (Aβ)n . d .
√√
n.d. [24]
APP23 Swedish — Thy1 (APP) 6m n.d. 14–18m — [25]
APP751SLx
PS1M146L
Swedish,
London M146L Thy1 (APP)
HMG-CoA (PS1) 3m
√
17m
√
[16]
APP751SL/
PS1KI
Swedish,
London
M233T,
L235P
Thy1 (APP) PS1
knockin 2m
√
6m
√
[18]
5XFAD
Swedish,
Florida,
London
M146L,
L286V Thy1 (APP, PS1) 2m
√
9m
√
[28]
TBA2 — — Thy1 (AbpE3−42)2 m
√
2m n.d. [42]
APPE693Δ Japanese — Prp (APP) —
√
24m
√
[14]
3xTg Swedish M146V Thy1 (APP, Tau)
PS1 knockin 6m
√
n.d.
√
[20]
APP/tau Swedish — Prion Protein
(APP) Thy1 (Tau) 9m n.d. 9m n.d. [19]
TauPS2APP Swedish N141I (PS2) Thy1 (APP, PS2,
Tau) 4m n.d. — n.d. [46]
Aβ accumulation. No neuron loss could be observed in
the thalamus where on extracellular Aβ plaques, however,
in a comparable amount as in the cortex were present
[32]. A related observation was made in distinct cholinergic
brain stem nuclei (Mo5, 7N) in this mouse model, where
neuronal loss at 6 or 12 months of age correlated with the
presence of intraneuronal Aβ peptides [33]. Interestingly, a
signiﬁcant loss of parvalbumin- (PV)-positive interneurons
in CA1-2 (40%–50%) and calretinin- (CR)-immunoreactive
interneurons in the hilus and dentate gyrus (37%–52%) has
been recently reported in 10-month-old APP/PS1KI mice
[34]. This is in the range of PV- and CR-positive interneuron
losses in the dentate gyrus of postmortem brain specimen
from AD patients. In addition, a signiﬁcant neuron loss
has been found in the granule cell layer of the dentate
gyrus of 12-month-old APP/PS1KI mice, where abundant
Aβ deposition is present. This loss is likely due to local
extracellular plaque pathology [26], in combination with a
complete loss of neurogenesis already at the age of 6 months
[35, 36], which prevents any re-integration of new-born
neurons in that particular cell layer.
A recently described mouse model expressing mutant
APP and PS1 under the control of the murine Thy1
promoter (5XFAD mice) underscores the potential inﬂuence
of intraneuronal Aβ accumulation on the loss of neurons.
Analysis of cresyl violet stained sections in 9-month-old
mice revealed a reduced number of cortical layer 5 neurons,
a region with robust intracellular Aβ immunoreactivity.
The same holds true for the subiculum where neurons
where pale or entirely missing [28]. In a very recent report,
cortical and hippocampal neuron numbers were analysed by
design-based unbiased stereological methods in 12-month-
old female mice, verifying the discrete layer 5 neuron loss.
No reductions in neuron numbers and no intraneuronal
Aβ immunoreactivity were detected in the CA1 layer of the
hippocampus adding further evidence to the assumption
that intraneuronal Aβ accumulation is closely associated
with neuron loss [37]. These mice also show synaptic
alterationsdemonstratedbyadeclineinsynaptophysinlevels
a l r e a d ya t4m o n t h so fa g ea sw e l la ss i g n i ﬁ c a n t l yr e d u c e d
syntaxin and PSD-95 levels at the age of 9 months [28].
Besides full-length Aβ peptides ending at amino acid
40 or 42, N-terminally truncated peptides have recently
gained in importance. One of the most abundant truncated
peptides in AD brain is AβpE3–42 carrying a pyroglutamate
(pE) at position 3 [38]. It has been demonstrated that this
peptide is characterized by a higher aggregation propensity
[39], stability [40], and increased toxicity compared to full-
length Aβ [41]. Recently in vivo toxicity of this peptide has
been demonstrated in a mouse model expressing AβpE3–42
in neurons under the control of the murine Thy1 promoter.
Glutamate (E) at position three of Aβ has been mutated
into glutamine (Q), as it is well established that glutamine
becomes much faster converted into pyroglutamate. These
mice showed a severe neurological phenotype with prema-
ture death and abundant loss of cerebellar Purkinje cells
[42].
Very recently, a new transgenic mouse model express-
ing human APP with the APPE693Δ mutation has been
published [14]. This mutation has been initially described
in a Japanese pedigree showing Alzheimer’s-type dementia
and is characterized by decreased total Aβ secretion but
increasedresistancetoproteolyticdegradationandenhanced
oligomerization [43]. The resulting transgenic mice dis-
played intraneuronal accumulation of Ab oligomers staring
at the age of 8 months, however, no extracellular Aβ plaque
formation could be detected even at the age of 24 months. In
addition, micro-and astroglial accumulation was observed,4 International Journal of Alzheimer’s Disease
as well as a signiﬁcant decrease in the number of NeuN-
positive cells in the hippocampal CA3 region at 24 months of
age compared to age-matched nontransgenic littermates and
transgenic mice expressing wild-type APP. Furthermore, an
age-dependent decrease in synaptophysin levels was shown
by means of immunohistochemistry starting at the age of
8 months, which coincides with impairments in synaptic
plasticity as shown by in vivo electrophysiology [14] (see
Table 1).
3. APP andTau Transgenic MouseModels
Recentlyatripletransgenicmousemodelhasbeendeveloped
expressing both mutant APP (Swedish) and Tau (P301L) on
a mutant PS1 knockin background (3xTg-AD mice) [20].
Intracellular Aβ is apparent between 3 and 4 months in
these mice and precedes the deposition of extracellular Aβ
peptides starting around the age of 6 months. At this time
point synaptic plasticity was already strongly compromised
in these mice, as shown by impaired long-term potentiation
[20].BehavioralanalyseshavesuggestedthatintracellularAβ
accumulation is functionally linked to cognitive impairment
in these mice, as they develop deﬁcits in long-term retention
at the age of 4 months, a time point prior to plaque
deposition where only intracellular Aβ is present [44].
Morphological alterations of hippocampal synapses have
been characterized in 13-month-old 3xTg-AD mice and
age-matched PS1KI control mice. The numeric density of
synapses, the average synaptic contact area as well as the
synaptic surface density were not altered, however, 3xTg-
AD mice showed a signiﬁcant reduction in the fraction of
perforated synapses, which is believed to represent a reliable
indirect index of synaptic plasticity [45].
A double transgenic mouse line based on Tg2576 mice
crossedwithVLWmice(TauG272V,P310L,R406W)showed
increased amyloid deposition at the age of 16 months com-
pared to APP single transgenic mice. In addition, APP/Tau
mice revealed a signiﬁcantly reduced neuron number in the
entorhinal cortex at 9 months of age compared to APP single
transgenic, Tau single transgenic, or wild-type mice, which
were extended to the CA1 layer at the age of 16 months.
It was further reported that cell death in these APP/Tau
mice preceded overt amyloid plaque formation and NFT
formation and did not correlate with amyloid burden in any
of the regions examined [19].
Another new transgenic mouse line expressing mutant
APP, Presenilin-2 (PS2), and Tau (TauPs2APP) has been
recently described. It has been demonstrated that Aβ in
these triple transgenic mice impacts on Tau pathology by
increasing the phosphorylation of Tau at serine 422. How-
ever, despite of increased levels of phosphorylated Tau, no
diﬀerencesinneuronnumbersweredetectedinhippocampal
subregions comparing triple transgenic and wild-type mice.
Quantitative receptor autoradiography revealed signiﬁcantly
reduced mGluR2 levels in aged triple transgenic mice,
which were however not diﬀerent from the PS2APP double
transgenic control line, arguing against a prominent role of
increased Tau phosphorylation [46].
4. Conclusion
In summary, there is no doubt that transgenic mice have
been proven to be valuable model systems in modern AD
research. There is accumulating evidence that signiﬁcant
neuron loss in APP/Aβ-related transgenic mice is linked to
intraneuronal Aβ accumulation, as this pathological alter-
ation precedes neurodegeneration in almost all the models
where neuronal loss has been convincingly reported. If this
is also true for the human situation is currently less clear, as
intraneuronalAβseemstobeatransientphenomenonwhich
might not be adequately detected in end-stage AD patients.
Although it has been shown that reductions in Tau levels
prevented behavioral deﬁcits in transgenic mice expressing
human amyloid precursor protein and also protected both
transgenic and nontransgenic mice against excitotoxicity
[47], overexpression of mutant Tau in APP or APP/PS
transgenic mice does not result in dramatic eﬀects on
neurodegeneration. One possibility might be that murine
neurons could be devoid of the downstream pathways
necessary for Aβ-induced toxicity leading to tau aggregation
in NFTs in human AD brain.
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